DOCSLIB.ORG

Médecine Nucléaire Special Edition 2021: Nuclear Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Médecine Nucléaire Special Edition 2021: Nuclear Medicine nucléaire 2021-6_Layout 1 21-04-14 11:04 Page 1 LE PATIENT LE SEUL MAGAZINE DE TOUS LES PROFESSIONNELS DE LA SANTÉ ÉDITION SPÉCIALE 2021: MÉDECINE NUCLÉAIRE SPECIAL EDITION 2021: NUCLEAR MEDICINE Les femmes de la médecine nucléaire Women in nuclear medicine AVRIL 2021 VOL 15 • NO 1 5,95 $ Envoi de publications Société canadienne des postes. canadiennes. Contrat de vente n canadiennes. Marie Curie et sa fille / and her daughter Irène Joliot-Curie o 40011180. FUNCTIONAL LUNG IMAGING BENEFITS V/Q SPECT TECHNEGAS™ Proven diagnostic Minimally Detects Low radiation accuracy invasive subsegmental burden with high sensitivity and aiding patients’s confort and Pulmonary 26-36 times less absorbed specificity 1 compliance 2 Embolism (PE) 3 dose to breast of females 4 Technegas™ has minimal exclusion criteria and may be administered to most patients4-6 including: Renal impaired | Contrast allergy | Diabetics Chronic Obstructive Pulmonary Disease (COPD) | Critically ill Pregnant Radiation Exposure (mSv) V/Q SPECT TECHNEGAS™ IN NUCLEAR GUIDELINES CTPA (64 slice) 20 The EANM Guidelines7 strongly recommend ventilation-perfusion single CTPA (4-16 slice) 5.4 photon emission computed tomography (V/Q SPECT) as it allows the diagnosis of PE with accuracy even in the presence of COPD and pneumonia. V/Q SPECT LDCT 3.1 The CANM Guidelines8 consider Technegas™ as the agent of choice V/Q SPECT 2.1 in COPD population because it has less central airway deposition, better peripheral penetration and it does not wash away quickly as traditional Table 1: Radiation exposure 8 (mSv) aerosols. Only a few breaths are sufficient to achieve an adequate amount of (adapted from CANM guidelines, 2018) activity in the lungs, reducing time and personnel exposure. All PE’s should have a final control 3 months after diagnosis to assess final reperfusion and to benefit from the availability of 95% a baseline exam in case of recurrent symptoms. Low radiation exposure allows repeated studies ( 90% table 1). 85% With the uptake in SPECT imaging, V/Q SPECT results are 80% seen as being superior to planar imaging and computed 75% tomography (CTPA) when comparing sensitivity, negative 70% predictive value and accuracy (table 2).1 Sensitivity Specificity PPV NPV Accuracy CTPA V/Q SPECT V/Q Planar Therefore, in situations of acute PE, chronic PE, pregnancy, Table 2: Diagnostic ability of CTPA, V/Q SPECT and V/Q Planar to paediatrics and the COPD population, V/Q SPECT can be detect PE (adapted from Hess et al, 2016) considered as a first-line investigation due to its high sensitivity 8 References and specificity, low radiation and no adverse reactions. 1. Hess S, et al. Semin Thromb Hemost 2016; 5. Miles S, et al. Chest 2009; 136: 1546-1553 42: 833–845 6. Nasr A, et al. EC Pulmon and Respir Medicine 2. Sánchez-Crespo A, et al. Nucl Med Commun 2017; 4(3): 85-91 2008; 29(2): 173-177 7. Bajc M, et al. Eur J Nucl Med Mol Imaging 46, 3. Grüning T, et al. Clin Imaging 2014; 38(6): 2429–2451 831-835 8. Leblanc M , et al. CANM Guidelines 2018; 4. Isidoro J, et al. Phys Med 2017; 41: 93-96 published Nov 2018 Technegas™ is not yet available for sale in the USA. Last revision (A4): v.2.1 (14/Apr/2021) For more information please visit www.cyclomedica.ca or email [email protected] Page 1/1 nucléaire 2021-6_Layout 1 21-04-14 11:04 Page 3 SOMMAIRE Éditeur Ronald Lapierre 4 INTRODUCTION TO THE SPECIAL EDITION 2021: Comité d’orientation NUCLEAR MEDICINE Francois Lamoureux, M.D.,M.Sc, président Jean-Luc Urbain M.D., Ph.D. 6 LES AVANCÉES MÉDICO-PHARMACOLOGIQUES L’ÉNERGIE NUCLÉAIRE : Directrice de la publication L’ARME SUPRÊME DES MÉDECINS NUCLÉISTES Dominique Raymond 8 INTERVIEW Développement des affaires LES FEMMES DE LA MÉDECINE NUCLEAIRE et marketing Nicolas Rondeau-Lapierre WOMEN IN NUCLEAR MEDICINE Le Prix Hippocrate 20 DACRYOSCINTIGRAPHY IN PATIENTS WITH EPIPHORA Francine Champoux, directrice générale Tél: 514-755-4029 22 NUCLEAR MEDICINE THERANOSTICS [email protected] 26 IODINE 131: HEADING TO A CENTURY OF THERANOSTICS ! Direction artistique et impression Le Groupe Communimédia inc. 28 LE CANCER DU SEIN [email protected] www.communimedia.ca 30 BRAIN SPECT IN HEAD INJURY Correction-révision 32 THE ROLE OF NUCLEAR MEDICINE Anik Messier IN DETECTION OF CARDIAC AMYLOIDOSIS Publicité Nicolas Rondeau-Lapierre 37 THE CANADIAN ASSOCIATION OF NUCLEAR MEDICINE Tél. : (514) 331-0661 ASSOCIATION CANADIENNE DE MÉDECINE NUCLÉAIRE [email protected] 40 CANM CARDIAC AMYLOID Les auteurs sont choisis selon l’étendue de leur PYP IMAGING GUIDELINES expertise dans une spécialité donnée. Le Patient ne se porte pas garant de l’expertise de ses colla- 50 ASSOCIATION DES MÉDECINS SPÉCIALISTES borateurs et ne peut être tenu responsable de leurs EN MÉDECINE NUCLÉAIRE DU QUÉBEC déclarations. Les textes publiés dans Le Patient n’engagent que leurs auteurs. 52 PRIX HIPPOCRATE 2020 : LES GAGNANTS Abonnement 4 numéros (1 an) 56 ENTREVUE AVEC LE DR. FRANCOIS LAMOUREUX Canada : 30 $ par année International : 46 $ (cdn) par année 58 INTERVIEW WITH DR. JEAN LUC URBAIN Pour vous abonner 60 INTERVIEW WITH DR. ALAN PACKARD Par correspondance : 1600, boul. Henri-Bourassa Ouest, Bureau 405 61 INTERVIEW WITH DR. MOHAMAD B. HAIDAR Montréal (Québec) H3M 3E2 64 ENTREVUE AVEC LE DR. NORMAN LAURIN Par téléphone : 514-331-0661 65 INTERVIEW WITH DR. DANIEL BADGER Le Patient est publié quatre fois par année 66 INTERVIEW WITH DR. MARK TULCHINSKY par les Éditions Multi-Concept inc. 1600, boul. Henri-Bourassa Ouest, Bureau 405 68 INTERVIEW WITH DR. ZVI BAR-SEVER Montréal (Québec) H3M 3E2 70 ENTREVUE AVEC Secrétariat : LE DR. CHRISTOPHER O’BRIEN Tél. : (514) 331-0661 Fax : (514) 331-8821 71 INTERVIEW DR. JULIANO JULIO CERCI Toutes les annonces de produits pharmaceuti- 72 ENTREVUE AVEC LE DR. FLORENT CACHIN ques sur ordonnance ont été approuvées par le Conseil consultatif de publicité pharmaceutique. Dépôt légal : Pensons environnement! Bibliothèque du Québec Bibliothèque du Canada Le Patient maintenant Convention de la poste-publication disponible sur internet No 40011180 Vous désirez consulter votre magazine en ligne? Rien de plus simple! Rendez-vous au : www.lepatient.ca LE PATIENT Vol.15, nº 1 3 nucléaire 2021-6_Layout 1 21-04-14 11:05 Page 4 INTRODUCTION TO THE SPECIAL EDITION 2021: NUCLEAR MEDICINE François Lamoureux Jean-Luc Urbain M.D.,M.Sc., FRCPC M.D., Ph.D., CPE, FASNC President, CANM Past President, CANM rancois Lamoureux and I are thrilled to introduce publications, the Royal Swedish Academy of Sciences to our numerous readers this new issue of the awarded in 1903 Marie Curie, her husband Pierre Curie Finternationally acclaimed Nuclear Medicine and Henri Becquerel the Nobel Prize in Physics. Her magazine LePatient. daughter, Irene Joliot-Curie, who followed her mother’s steps also received with her husband, Frederic Joliot, The lack of concerted efforts in research and the Nobel Prize in Chemistry Marie Curie, her husband development of new radiopharmaceuticals in the last and Henri Becquerel were awarded in 1903, the Nobel part of the 20th century created a climate of uncertainty Prize in Physics for their discovery of artificial about the field of nuclear medicine at the eve of the radioactivity. 21st century. In a very interesting and remarkable turn of events, the development of diagnostic and Too often the women contributions to the field of therapeutic radiopharmaceuticals based on diseases nuclear medicine are unsung and unnoticed. The first “ To contribute genotypes and phenotypes and so-called isotopes pairs part of the magazine is dedicated to the memory of actively to the (Nuclear Theranostics) have triggered a true Marie and Irene Curie who died of leukemia from rebirth of Nuclear renaissance of the field of Nuclear Medicine. the exposure to radiation exposure resulting from their Medicine, we potentials of becoming the new holy grail of nuclear discovery of and work on radioactivity. The month of should be inspired medicine. March is Women History Month. Through a series of by the illustrious, interviews, we also wanted to celebrate in this issue of remarkable and Through their exquisite sensitivity and specificity, the magazine, the courage, strength, leadership, exemplary life and Nuclear Theranostics, in combination with hybrid achievements, and challenges of contemporary women colleagues in Nuclear Medicine. professional imagers (SPECT/CT, PET/CT and PET/MR), will undoubtfully play a major role in precision medicine by achievements of significantly improving patient disease management, In the second part of the magazine, you will find the Marie Curie whom particularly in oncology. This is nicely elaborated in the genuine testimony of international leaders in the field We consider the recent article published in the recnt issue of the of Nuclear Medicine who are expressing their views on mother of Nuclear Macleans magazine https://www.healthinsight.ca/ the current state of affairs on our field and wishes for Medicine. ” innovations/ushering-in-a-new-era-of-cancer-care/#. the rebirth of our specialty. As exhilarating as the rebirth of Nuclear Medicine can Finally, we hope you will enjoy reading a potpourri of be, it is also full of challenges. A fully integrated articles that illustrate nicely the current and future of diagnostic and therapeutic specialty, the practice of our beloved specialty. nuclear medicine requires in depth knowledge in many different fields of medicine, complex imaging François Lamoureux equipment along with an in depth understanding of Jean-Luc Urbain patient’s diseases and management, health care systems and health care economics. The needs for this type of complex knowledge, experience and expertise represents both unique opportunities and significant challenges for medical school and nuclear medicine centers across the globe. To contribute actively to the rebirth of Nuclear Medicine, we should be inspired by the illustrious, remarkable and exemplary life and professional achievements of Marie Curie whom we consider the mother of Nuclear Medicine.
Load more

Recommended publications
  • Lacrimal Scintigraphy
    LACRIMAL SCINTIGRAPHY Lacrimal Scintigraphy RO Boer, Medical Centre, Alkmaar (Retired) NOTE: no changes have been made since the version of 2007 1. Introduction A standardised volume of 10 μl 99mTc pertechnetate is instilled into the patient’s conjunctival sac using a micro-pipette. In principle, the quantity must be as small as possible, since any increase in the very small tear reservoir can lead to contamination of the eyelids and thus adversely affect the interpretability of the investigation. In contradistinction to the already well-established xray investigation whereby at all times outside influence is exerted on the tear drainage, the aim of this tracer investigation is to study the natural tear drainage. Normally, tears are drained from the conjunctival sac to the lacrimal sac (saccus lacrimalis), then to the naso-lacrimalduct (ductus nasolacrimalis) and finally to the nose and pharynx. 2. Methodology This guideline is based on available scientific literature on the subject, the previous guideline (Aanbevelingen Nucleaire Geneeskunde 2007), international guidelines from EANM and/or SNMMI if available and applicable to the Dutch situation. 3. Indications Epiphora (watering of the eye) is the initial indication. The ability to adequately manipulate the lacrimal pathways in order to improve drainage is closely linked to the indication. This is often achived through surgical procedures such as DCR (dacryocystorhinostomy) or DCP (dacryocystorhinoplasty, ‘angioplasty’ of the lacrimal pathways). Thereafter, the effect of these interventions can be evaluated by means of lacrimal scintigraphy. 4. Relation to other diagnostic procedures The Anel test is performed by cannulating the lower lacrimal point and injecting physiological saline. When the system becomes patent, the patient will taste salt.
    [Show full text]
  • FDA-Approved Radiopharmaceuticals
    Medication Management FDA-approved radiopharmaceuticals This is a current list of all FDA-approved radiopharmaceuticals. USP <825> requires the use of conventionally manufactured drug products (e.g., NDA, ANDA) for Immediate Use. Nuclear medicine practitioners that receive radiopharmaceuticals that originate from sources other than the manufacturers listed in these tables may be using unapproved copies. Radiopharmaceutical Manufacturer Trade names Approved indications in adults (Pediatric use as noted) 1 Carbon-11 choline Various - Indicated for PET imaging of patients with suspected prostate cancer recurrence based upon elevated blood prostate specific antigen (PSA) levels following initial therapy and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI) to help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation 2 Carbon-14 urea Halyard Health PYtest Detection of gastric urease as an aid in the diagnosis of H.pylori infection in the stomach 3 Copper-64 dotatate Curium Detectnet™ Indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients 4 Fluorine-18 florbetaben Life Molecular Neuraceq™ Indicated for Positron Emission Tomography (PET) imaging of the brain to Imaging estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline 5 Fluorine-18
    [Show full text]
  • Nuclear Medicine
    2013 RSNA (Filtered Schedule) Sunday, December 01, 2013 10:45-12:15 PM • SSA18 • Room: S505AB • Nuclear Medicine (PET/CT in Oncology) 12:30-01:00 PM • CL-NMS-SUA • Room: S503AB • Nuclear Medicine - Sunday Posters and Exhibits (12:30pm - 1:00pm) 01:00-01:30 PM • CL-NMS-SUB • Room: S503AB • Nuclear Medicine - Sunday Posters and Exhibits (1:00pm - 1:30pm) 02:00-03:30 PM • RC111 • Room: S505AB • Multi-modal Imaging Workup for Alzheimer's Disease, Parkinson's Disease, and Related Disorders: Case-based App... Monday, December 02, 2013 08:30-10:00 AM • RC217 • Room: S504CD • PET-MR/Hyperpolarized MR 08:30-12:00 PM • VSNM21 • Room: S505AB • Nuclear Medicine Series: Assessment of Cancer Treatment Response: Updates 12:15-12:45 PM • CL-NMS-MOA • Room: S503AB • Nuclear Medicine - Monday Posters and Exhibits (12:15pm - 12:45pm) 12:45-01:15 PM • CL-NMS-MOB • Room: S503AB • Nuclear Medicine - Monday Posters and Exhibits (12:45pm - 1:15pm) 03:00-04:00 PM • SSE08 • Room: E353C • ISP: Gastrointestinal (Oncology: Staging and Distant Metastases) 03:00-04:00 PM • SSE19 • Room: S504CD • Nuclear Medicine (Quantitative Imaging) 03:00-04:00 PM • SSE20 • Room: S505AB • Nuclear Medicine (SPECT/CT) Tuesday, December 03, 2013 08:30-10:00 AM • MSCC31 • Room: S406A • Case-based Review of Nuclear Medicine: PET/CT Workshop-Head and Neck Cancers (In Conjunction with SNMMI) (An I... 08:30-10:00 AM • RC321 • Room: S102D • Medical Physics 2.0: Nuclear Imaging 08:30-10:00 AM • RC351 • Room: E353C • CT/PET in the Abdomen and Pelvis: How and When (How-to Workshop) (An Interactive Session) 08:30-12:00 PM • VSNM31 • Room: S505AB • Nuclear Medicine Series: Non-FDG PET Radiotracers in Oncology 10:30-12:00 PM • MSCC32 • Room: S406A • Case-based Review of Nuclear Medicine: PET/CT Workshop-Cancers of the Abdomen and Pelvis (In Conjunction with ..
    [Show full text]
  • Dacryocystography: from Theory to Current Practice
    Annals of Anatomy 224 (2019) 33–40 Contents lists available at ScienceDirect Annals of Anatomy jou rnal homepage: www.elsevier.com/locate/aanat SPECIAL ISSUE REVIEW ଝ Dacryocystography: From theory to current practice a,∗ a,b a Swati Singh , Mohammad Javed Ali , Friedrich Paulsen a Institute of Clinical and Functional Anatomy, Friedrich-Alexander University of Erlangen-Nürnberg, Germany b Govindram Seksaria Institute of Dacryology, L.V. Prasad Eye Institute, Hyderabad, India a r t a b i c l e i n f o s t r a c t Article history: Purpose: To provide a review and an update on dacryocystography (DCG) and its relevance in the current Received 11 March 2019 era. Received in revised form 19 March 2019 Methods: The authors performed a PubMed search of all articles published in English on DCG, digital Accepted 20 March 2019 subtraction-DCG (DS-DCG), computed tomographic DCG (CT-DCG) and magnetic resonance-DCG (MR- DCG). Data analyzed include the indications, techniques, interpretations, complication and limitations. Keywords: Results: Dacryocystography has been used for illustrating the morphological and functional aspects of Lacrimal the lacrimal drainage system (LDS). Subtraction DCG provides the precise location of the alterations and Epiphora Dacryocystography acceptably delineates stenosis or an obstruction. Transit time for contrast into the nose varies widely across the studies. Low osmolality iodinated contrast media are tolerated well for DS-DCG and CT-DCG. Subtraction dacryocystography MR dacryocystography However, normal saline either mixed with lidocaine or alone provided similar image quality as obtained CT-DCG with gadolinium for MR-DCG. CT-DCG provides useful information in complex orbitofacial trauma and MR-DCG lacrimal tumors.
    [Show full text]
  • SNMMI Nuclear Medicine Technology Competency Based Curriculum
    Nuclear Medicine Technology Competency- Based Curriculum Guide 5th Edition Introduction Competency-based education in nuclear medicine technology focuses on those elements necessary to become an entry-level nuclear medicine technologist. Emphasizing competencies communicates entry-level knowledge, skills, attitudes, and behaviors that the nuclear medicine technology curriculum must address and that employers can expect of graduates. Competency- based education allows more flexibility in pedagogical approaches to achieve these essential competencies. The competencies are divided into eight sections: 1. Radiation Safety 2. Instrumentation, Quality Control and Quality Assurance 3. Radiopharmacy and Pharmacology 4. Diagnostic and Therapeutic Procedures 5. Patient Care 6. Professionalism and Interpersonal Communication Skills 7. Organization Systems-Based Practice 8. Research Methodology Each section lists the competencies that must be achieved by the entry level nuclear medicine technologist. The rigor of the nuclear medicine technologist entry-level competencies is such that a significant body of knowledge, skills, and experience is necessary to achieve them. This level of rigor is consistent with the Society of Nuclear Medicine and Molecular Imaging—Technologist Section’s (SNMMI-TS) recommendation that the entry-level degree for a nuclear medicine technologist should be at the baccalaureate level. The content listed under the competencies is intended to be used as a guide for what may be included in a program’s curriculum to achieve minimal competency in each area. The specific content listed should be used at the program’s discretion to meet individual curricular and accreditation needs. The content in its entirety is not considered mandatory, and other pedagogies may equally meet each program’s needs.
    [Show full text]
  • Infrequently Performed Studies in Nuclear Medicine: Part 1
    Infrequently Performed Studies in Nuclear Medicine: Part 1 Anita MacDonald and Steven Burrell Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada clinical and technical aspects of each study are discussed, Nuclear medicine is a diverse field with a large number of differ- along with a brief comparison of alternative assessment ent studies spanning virtually all organ systems and medical spe- modalities. Included in Part 1 of this article are dacroscin- cialties. Many nuclear medicine procedures are performed tigraphy, LeVeen shunts, scintimammography, right-to-left routinely; others may be performed only rarely, sometimes less (R-L) shunts, left-to-right (L-R) shunts, and heat-damaged than once per year. The infrequent nature of many studies makes it challenging to retain relevant knowledge and skills. This 2-part red blood cell (RBC) studies. Part 2 will cover cerebral article provides a review of several infrequently performed stud- spinal fluid shunt, brain death, testicular scan, quantitative ies. The topics discussed in Part 1 include dacroscintigraphy, lung perfusion scan, lymphoscintigraphy, and salivary gland LeVeen shunts, scintimammography, right-to-left shunts, left- scintigraphy studies. to-right shunts, and heat-damaged red blood cells. After reading this article, the reader should be able to list and describe the in- DACROSCINTIGRAPHY (LACRIMAL GLAND STUDY) dications for each study, list the doses and describe their proper method of administration, and describe problems that may arise The lacrimal glands are located in the lateral superior during the imaging procedure and how they should be handled. portion of each orbit.
    [Show full text]
  • Financial and Operational Management of Nuclear Medicine Departments in the NHS Within the London Area
    Imagem Sara Raquel Costa Soares Financial and Operational Management of Nuclear Medicine Departments in the NHS within the London Area Dissertação de Mestrado em Gestão e Economia da Saúde, apresentada à Faculdade de Economia da Universidade de Coimbra Orientadora: Drª. Prof. Carlota Quintal Setembro de 2015 Cover (FEUC template) and illustration: Sara Soares Sara Raquel Costa Soares Financial and Operational Management of Nuclear Medicine Departments in the NHS within the London Area Dissertação de Mestrado em Gestão e Economia da Saúde, apresentada à Faculdade de Economia da Universidade de Coimbra para obtenção do grau de Mestre Orientadora: Prof. Doutora Carlota Quintal Coimbra, 2015 Acknowledgments I would like to thank my supervisor, Prof. Drª. Carlota Quintal, for the patient guidance, encouragement and advice she has provided during this last year. I have been extremely lucky to have a supervisor who cared about my work, and who responded to my questions and queries so promptly. I am very grateful for all the interviewees that made this study possible. Without their cooperation and understanding, I would not have learnt so much like I did. I must express my gratitude to Stefan, my boyfriend, for his continued support and encouragement. He must know more about this work than me, after reading it so many times. Sorry for the sleepless nights. I am thankful for the patience of my mother, father and brother who experienced all of the ups and downs of my research. Completing this work would have been all the more difficult were it not for the support and friendship provided by my work colleagues of the Nuclear Medicine department at King´s College Hospital.
    [Show full text]
  • 202158Orig1s000
    &(17(5)25'58*(9$/8$7,21$1' 5(6($5&+ APPLICATION NUMBER: 2ULJV &/,1,&$/3+$50$&2/2*<$1' %,23+$50$&(87,&65(9,(: 6 Clinical Pharmacology Review _ NDA 202-158 Submission Dates January 4, 2013 SDN 1 January 22, 2013 SDN 2 February 15. 2013 SDN 6 June 24, 2013 SDN 12 July 10, 2013 SDN 13 Type/Category Original-1 (Type 5 - New Formulation or New Manufacturer) Brand Name Sodium Pertechnetate Tc99m Injection USP Generic Name Sodium Pertechnetate Tc99m Injection USP Proposed Indication Sodium Pertechnetate Tc99m Injection produced by a TechneGen Generator System is a diagnostic radiopharmaceutical agent intended for use in children and adults for the following indications: Brain Imaging (including cerebral radionuclide angiography) Thyroid Imaging Salivary Gland Imaging Placenta Localization Blood Pool Imaging (including radionuclide angiography) Urinary Bladder Imaging (direct isotopic cystography) for detection of vesico-ureteral reflux. In addition, it is indicated for use in adults for Nasolacrimal Drainage System Imaging (dacryoscintigraphy). Sodium Pertechnetate Tc99m Injection is also used to reconstitute a variety of reagent kits, commonly referred to as Technetium Tc99m Kits, and with each reconstituted kit used for specified diagnostic imaging indications. (b) (4) Dose (depending on indication) Route of Administration Intravenous Injection; oral; instillation in bladder or eyes Applicant Northstar Medical Radioisotopes, LLC 1 Reference ID: 3379891 Reviewing Division Division of Clinical Pharmacology 5 (DCP 5) Medical Division Division of Medical Imaging Products (DMIP) Primary Reviewer Christy S. John, Ph.D. Secondary Reviewer Gene Williams, Ph.D. _ Table of Contents Page Cover Page 1 Table of Contents 2 1.
    [Show full text]
  • Development of a Radiochemistry Laboratory for the Production of Tc-99M Using Neutron Activation
    AC 2007-620: DEVELOPMENT OF A RADIOCHEMISTRY LABORATORY FOR THE PRODUCTION OF TC-99M USING NEUTRON ACTIVATION Sheldon Landsberger, University of Texas-Austin Dr. Sheldon Landsberger is the Coordinator of the Nuclear and Radiation Engineering Program at the University of Texas at Austin and teaches a graduate course in Nuclear and Radiochemistry. Jessica Rosinski, University of Texas-Austin Paul Buckley, Lewis-Clark State College Dan Dugan, Washington State University James Elliston, Washington State University Roy Filby, Washigton State University Jeremy Lessman, Washington State University Alena Paulenova, Oregon State University Page 12.519.1 Page © American Society for Engineering Education, 2007 DEVELOPMENT OF A RADIOCHEMISTRY LABORATORY FOR THE PRODUCTION OF 99m Tc USING NEUTRON ACTIVATION Abstract Many health care professionals increasingly rely on the use of radiopharmaceuticals in diagnosis and therapy. 99m Tc is the world’s most widely used radioisotope in nuclear diagnostic imaging. A small amount of 99m Tc is incorporated in a carrier molecule and injected into the patient’s blood stream which is then used for imaging. Selective accumulation of the 99m Tc in specifically targeted internal organs is achieved through the design of the carrier molecule. Traditionally it is produced from fission of uranium to produce 99 Mo which then decays to 99m Tc. The goal of this work is to set up a comprehensive graduate radiochemistry laboratory to isolate 99m Tc using the neutron activation of stable ammonium molybdenate. Included in the laboratory is an overview of the nuclear medicine information of 99m Tc, the radiation dose received for specific medical diagnoses, and the construction of an efficiency curve for a germanium detector that can be used for activity measurements of other medical isotopes produced.
    [Show full text]
  • Evaluation of Lacrimal Drainage System by Radionuclide Original Article Dacryoscintigraphy in Patients with Epiphora
    Evaluation of lacrimal drainage system by radionuclide Article Original dacryoscintigraphy in patients with epiphora Sagili Chandrasekhara Reddy1, 2, Ahmad Zakaria3, Venkata Muralikrishna Bhavaraju3 1 Department of Ophthalmology, School of Medical Sciences, University Sains Malaysia, Kubang Kerian, Kelantan, Malaysia 2Department of Ophthalmology, Faculty of Medicine and Defence Health, National Defence University of Malaysia, Kem Sungai Besi, Kuala Lumpur, Malaysia 3Department of Nuclear Medicine, Radiotherapy and Oncology, School of Medical Sciences, University Sains Malaysia, Kubang Kerian, Kelantan, Malaysia (Received 4 August 2015, Revised 6 November 2015, Accepted 8 November 2015) ABSTRACT Introduction: This study was done to determine the site of obstruction in lacrimal drainage system in Asian patients suffering from epiphora and to determine the transit time taken for the tracer material to reach the lacrimal sac and the nasal cavity. Methods: Dacryoscintigraphy was performed using radionuclide technetium-99m pertechnetate (99mTc) in 34 patients suffering from unilateral or bilateral epiphora and in 3 cases of post-operative dacryocystorhinostomy. The site of obstruction was noted during the dynamic scintigraphy procedure. The time taken for the tracer material to reach the lacrimal sac in all the eyes and the nasal cavity in the eyes with patency of nasolacrimal duct was determined. Results: Complete obstruction of nasolacrimal duct (NLD) was noted in all 22 unilateral cases. However, in 4 of the contralateral asymptomatic eyes in these patients complete obstruction of NLD was detected. Out of 12 bilateral cases, complete obstruction of NLD was noted in both eyes in 4 cases, and in one eye only in 8 cases. There was partial obstruction of NLD in the other eye in these 8 patients.
    [Show full text]
  • Advertising (PDF)
    Introducing TM - @- — @ IODOHIPPURATE0 :.,.@@,123INJECTiON Normal Transp@nt Renogram1 -. HighDetectorEfficiency 0• 9 P9999,9999 lodohippurateSodiumI 131Injection,0.15mCi LowCountRate Low DetectorEfficiency NEPHROFLOWprovidesbettercountingstatisticsandhigherdatadensity. ‘Reference:Dataon file. Medi-Ptiysics, Inc.. Richmond. CA ‘NaHTIftrvstaI . Particularly useful in obstructed patients . Slight advantage in photon intensity . Major advantage in ¼inch crystal efticiency •Imagingshouldbe performedas closeto calibrationtime as possible 744 b4@ 514 41) :so 20 14) IERCENT ABS@RV1I()N ComparisonofI 123andI 131 Characteristic 1123 1131 Modeof Decay Electroncapture Beta Half-Life 13.2hours 193hours PrincipalGamma Energy(keV) 159 364 Intensity 84% 82% Half-Valuelayer,lead,cm 0.037 0.24 DetectionEfficiency: ¼―Nal (TI ) crystal 74.5% 22.5% NEPHROFLOW'@ IODOHIPPURATESODIUMI 123INJECTION Forcomplstspse.cdblng InformationconsultpackagsInsert,abrlefsummaryof whichfollows: DESCRIPTION:IodohippurateSodiumi l23lnjection issupplied asasterile, apyrogenic, Radlopharmaceuticals should be used only by physicians who are qualified by training aqueous,isotonicsalinesolutionfor intravenousadministration.Eachmilliliterof the and experience in the safe use and handling of radsonuclidesand whose experience and solutioncontains37 megabecquerels(1 mtlhcurie)lodohippurateSodiumI 123 at training havebeenapproved bytheapproprlategovemmentagencyauthorizedtollcense calibrationtime, 2 milligramslodohippurateSodium,I percentbenzylalCOhOl(as a the useofradionuclides.
    [Show full text]
  • In Evaluation of Tear Drainage System by Dacryoscintigraphy
    Nuclear Medicine Review 2018, 21, 2: 75–78 DOI: 10.5603/NMR.a2018.0021 Copyright © 2018 Via Medica Original ISSN 1506–9680 The role of “after washing imaging” in evaluation of tear drainage system by dacryoscintigraphy Toktam Massoudi, Hamed Shayegani, Ramin Sadeghi Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran [Received 6 II 2018; Accepted 4 IV 2018] Abstract BACKGROUND: The aim of this study was to evaluate the efficacy of “after washing” imaging in interpretation of dacryoscin- tigraphy as a functional imaging technique used in evaluation of tearing problems. MATERIALS AND METHODS: 300 nasolacrimal systems were studied. 100 µCi of technetium-99m sodium pertechnetate as drops of activity (10 µL) were placed into the inferior fornix of each eye. Dynamic images were obtained for 15 minutes in the sitting position. “After washing” phase was done by placing a drop (10 µL) of normal saline in each eye and external ocular massage for an additional 10 minutes. The imaging patterns for each eye in the first dynamic phase and after washing phase were recorded, separately. RESULTS: First dynamic phase demonstrated a sensitivity of 97.4% and specificity of 22.6%. After washing phase showed a sensitivity of 91.2% and specificity 75.5%. After washing test, the obstruction pattern changed to “patent nasolacrimal duct” or “further progression” of the radiotracer to the nasolacrimal duct in the 25.1% and 24.4% of the nasolacrimal systems, respectively. CONCLUSIONS: After washing imaging is a useful method in dacryoscintigraphy which can improve the specificity of scan for diagnosis of lacrimal duct obstruction.
    [Show full text]